Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,809 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti-CD3ε mAb in new-onset type 1 diabetes mellitus patients.
Vlasakakis G, Napolitano A, Barnard R, Brown K, Bullman J, Inman D, Keymeulen B, Lanham D, Leirens Q, MacDonald A, Mezzalana E, Page K, Patel M, Savage CO, Zamuner S, van Maurik A. Vlasakakis G, et al. Among authors: macdonald a. Br J Clin Pharmacol. 2019 Apr;85(4):704-714. doi: 10.1111/bcp.13842. Epub 2019 Feb 5. Br J Clin Pharmacol. 2019. PMID: 30566758 Free PMC article. Clinical Trial.
Temporal pharmacokinetic/pharmacodynamic interaction between human CD3ε antigen-targeted monoclonal antibody otelixizumab and CD3ε binding and expression in human peripheral blood mononuclear cell static culture.
Page KR, Mezzalana E, MacDonald AJ, Zamuner S, De Nicolao G, van Maurik A. Page KR, et al. Among authors: macdonald aj. J Pharmacol Exp Ther. 2015 Nov;355(2):199-205. doi: 10.1124/jpet.115.224899. Epub 2015 Sep 4. J Pharmacol Exp Ther. 2015. PMID: 26341624
Phase I study of orally administered 14Carbon-isotope labelled-vistusertib (AZD2014), a dual TORC1/2 kinase inhibitor, to assess the absorption, metabolism, excretion, and pharmacokinetics in patients with advanced solid malignancies.
MacDonald A, Scarfe G, Magirr D, Sarvotham T, Charlton J, Brugger W, Dean E. MacDonald A, et al. Cancer Chemother Pharmacol. 2019 Apr;83(4):787-795. doi: 10.1007/s00280-019-03781-x. Epub 2019 Feb 13. Cancer Chemother Pharmacol. 2019. PMID: 30758651 Clinical Trial.
A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2- Primary Breast Cancer.
Robertson JFR, Evans A, Henschen S, Kirwan CC, Jahan A, Kenny LM, Dixon JM, Schmid P, Kothari A, Mohamed O, Fasching PA, Cheung KL, Wuerstlein R, Carroll D, Klinowska T, Lindemann JPO, MacDonald A, Mather R, Maudsley R, Moschetta M, Nikolaou M, Roudier MP, Sarvotham T, Schiavon G, Zhou D, Zhou L, Harbeck N. Robertson JFR, et al. Among authors: macdonald a. Clin Cancer Res. 2020 Aug 15;26(16):4242-4249. doi: 10.1158/1078-0432.CCR-19-3387. Epub 2020 Mar 31. Clin Cancer Res. 2020. PMID: 32234755 Clinical Trial.
E7-mediated repression of miR-203 promotes LASP1-dependent proliferation in HPV-positive cervical cancer.
Patterson MR, Meijers AS, Ryder EL, Wootton LM, Scarth JA, Evans D, Turner AL, Wasson CW, Darell JE, Theobald DA, Cogan JA, James CD, Wang M, Ladbury JE, Morgan IM, Samson A, Morgan EL, Macdonald A. Patterson MR, et al. Among authors: macdonald a. Oncogene. 2024 May 24. doi: 10.1038/s41388-024-03067-4. Online ahead of print. Oncogene. 2024. PMID: 38789663
Maternal exposure to bisphenols, phthalates, perfluoroalkyl acids, and trace elements and their associations with gestational diabetes mellitus in the APrON cohort.
Soomro MH, England-Mason G, Reardon AJF, Liu J, MacDonald AM, Kinniburgh DW, Martin JW, Dewey D; APrON Study Team. Soomro MH, et al. Among authors: macdonald am. Reprod Toxicol. 2024 May 21:108612. doi: 10.1016/j.reprotox.2024.108612. Online ahead of print. Reprod Toxicol. 2024. PMID: 38782143
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
Parker CC, Clarke NW, Cook AD, Kynaston H, Catton CN, Cross WR, Petersen PM, Persad RA, Saad F, Bower LC, Logue J, Payne H, Forcat S, Goldstein C, Murphy C, Anderson J, Barkati M, Bottomley DM, Branagan J, Choudhury A, Chung PWM, Cogley L, Goh CL, Hoskin P, Khoo V, Malone SC, Masters L, Morris SL, Nabid A, Ong AD, Raman R, Tarver KL, Tree AC, Worlding J, Wylie JP, Zarkar AM, Parulekar WR, Parmar MKB, Sydes MR; RADICALS investigators. Parker CC, et al. Lancet. 2024 May 16:S0140-6736(24)00548-8. doi: 10.1016/S0140-6736(24)00548-8. Online ahead of print. Lancet. 2024. PMID: 38763154 Free article.
2,809 results